Cargando…

Clinical Improvement Following Stroke Promptly Reverses Post-stroke Cellular Immune Alterations

Background and Purpose: Stroke induces immediate profound alterations of the peripheral immune system rendering patients more susceptible to post-stroke infections. The precise mechanisms maintaining stroke-induced immune alterations (SIIA) remain unknown. High-Mobility-Group-Protein B1 (HMGB-1) is...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogelgesang, Antje, Witt, Carl, Heuer, Christin, Schulze, Juliane, Gellrich, Juliane, von Sarnowski, Bettina, Langner, Sönke, Dressel, Alexander, Ruhnau, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504832/
https://www.ncbi.nlm.nih.gov/pubmed/31118917
http://dx.doi.org/10.3389/fneur.2019.00414
_version_ 1783416643427237888
author Vogelgesang, Antje
Witt, Carl
Heuer, Christin
Schulze, Juliane
Gellrich, Juliane
von Sarnowski, Bettina
Langner, Sönke
Dressel, Alexander
Ruhnau, Johanna
author_facet Vogelgesang, Antje
Witt, Carl
Heuer, Christin
Schulze, Juliane
Gellrich, Juliane
von Sarnowski, Bettina
Langner, Sönke
Dressel, Alexander
Ruhnau, Johanna
author_sort Vogelgesang, Antje
collection PubMed
description Background and Purpose: Stroke induces immediate profound alterations of the peripheral immune system rendering patients more susceptible to post-stroke infections. The precise mechanisms maintaining stroke-induced immune alterations (SIIA) remain unknown. High-Mobility-Group-Protein B1 (HMGB-1) is elevated for at least 7 days post-stroke and has been suggested to mediate SIIA. Patients with rapid clinical recovery of neurological deficits rarely develop severe infections. We therefore investigated whether rapid neurological recovery (either spontaneous or secondary to neurovascular recanalization therapy) alters the course of SIIA. National Institutes of Health Stroke Scale (NIHSS) served as surrogate marker for neurological improvement. Methods: Fluorescence-activated cell sorting was used to define leukocyte subpopulations. C-reactive protein (CRP), procalcitonin (PCT), HMGB-1, GM-CSF; IFN-β, IFN-γ, IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-17, IL-17F, IL-18, TNF-α, MIF, IL-8, MCP-1, MCP-4, MIP-3α, MIP-3β, Eotaxin, soluble IL-6 receptor, E-selectin, and P-selectin were analyzed by ELISA or Multiplex Assays. Serum miRNA expression changes were analyzed by qPCR. Results: Cellular parameters were similar in the improved and non-improved cohort on admission. In patients with rapid clinical recovery absolute and relative leukocyte, neutrophil, and lymphocyte numbers normalized promptly overnight. In contrast, HMGB-1 serum levels did not differ between the two groups. Nine miRNA were found to be differentially expressed between improved and non-improved patients. Conclusions: SIIA are detectable on admission of acute stroke patients. While it was assumed that post-stroke immunosuppression is rapidly reversed with improvement this is the first data set that shows that improvement actually is associated with a rapid reversal of SIIA demonstrating that SIIA require a constant signal to persist. The observation that HMGB-1 serum concentrations were similar in improved and non-improved cohorts argues against a role for this pro-inflammatory mediator in the maintenance of SIIA. Serum miRNA observed to be regulated in stroke in other publications was counter regulated with improvement in our cohort.
format Online
Article
Text
id pubmed-6504832
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65048322019-05-22 Clinical Improvement Following Stroke Promptly Reverses Post-stroke Cellular Immune Alterations Vogelgesang, Antje Witt, Carl Heuer, Christin Schulze, Juliane Gellrich, Juliane von Sarnowski, Bettina Langner, Sönke Dressel, Alexander Ruhnau, Johanna Front Neurol Neurology Background and Purpose: Stroke induces immediate profound alterations of the peripheral immune system rendering patients more susceptible to post-stroke infections. The precise mechanisms maintaining stroke-induced immune alterations (SIIA) remain unknown. High-Mobility-Group-Protein B1 (HMGB-1) is elevated for at least 7 days post-stroke and has been suggested to mediate SIIA. Patients with rapid clinical recovery of neurological deficits rarely develop severe infections. We therefore investigated whether rapid neurological recovery (either spontaneous or secondary to neurovascular recanalization therapy) alters the course of SIIA. National Institutes of Health Stroke Scale (NIHSS) served as surrogate marker for neurological improvement. Methods: Fluorescence-activated cell sorting was used to define leukocyte subpopulations. C-reactive protein (CRP), procalcitonin (PCT), HMGB-1, GM-CSF; IFN-β, IFN-γ, IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-17, IL-17F, IL-18, TNF-α, MIF, IL-8, MCP-1, MCP-4, MIP-3α, MIP-3β, Eotaxin, soluble IL-6 receptor, E-selectin, and P-selectin were analyzed by ELISA or Multiplex Assays. Serum miRNA expression changes were analyzed by qPCR. Results: Cellular parameters were similar in the improved and non-improved cohort on admission. In patients with rapid clinical recovery absolute and relative leukocyte, neutrophil, and lymphocyte numbers normalized promptly overnight. In contrast, HMGB-1 serum levels did not differ between the two groups. Nine miRNA were found to be differentially expressed between improved and non-improved patients. Conclusions: SIIA are detectable on admission of acute stroke patients. While it was assumed that post-stroke immunosuppression is rapidly reversed with improvement this is the first data set that shows that improvement actually is associated with a rapid reversal of SIIA demonstrating that SIIA require a constant signal to persist. The observation that HMGB-1 serum concentrations were similar in improved and non-improved cohorts argues against a role for this pro-inflammatory mediator in the maintenance of SIIA. Serum miRNA observed to be regulated in stroke in other publications was counter regulated with improvement in our cohort. Frontiers Media S.A. 2019-05-01 /pmc/articles/PMC6504832/ /pubmed/31118917 http://dx.doi.org/10.3389/fneur.2019.00414 Text en Copyright © 2019 Vogelgesang, Witt, Heuer, Schulze, Gellrich, von Sarnowski, Langner, Dressel and Ruhnau. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Vogelgesang, Antje
Witt, Carl
Heuer, Christin
Schulze, Juliane
Gellrich, Juliane
von Sarnowski, Bettina
Langner, Sönke
Dressel, Alexander
Ruhnau, Johanna
Clinical Improvement Following Stroke Promptly Reverses Post-stroke Cellular Immune Alterations
title Clinical Improvement Following Stroke Promptly Reverses Post-stroke Cellular Immune Alterations
title_full Clinical Improvement Following Stroke Promptly Reverses Post-stroke Cellular Immune Alterations
title_fullStr Clinical Improvement Following Stroke Promptly Reverses Post-stroke Cellular Immune Alterations
title_full_unstemmed Clinical Improvement Following Stroke Promptly Reverses Post-stroke Cellular Immune Alterations
title_short Clinical Improvement Following Stroke Promptly Reverses Post-stroke Cellular Immune Alterations
title_sort clinical improvement following stroke promptly reverses post-stroke cellular immune alterations
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504832/
https://www.ncbi.nlm.nih.gov/pubmed/31118917
http://dx.doi.org/10.3389/fneur.2019.00414
work_keys_str_mv AT vogelgesangantje clinicalimprovementfollowingstrokepromptlyreversespoststrokecellularimmunealterations
AT wittcarl clinicalimprovementfollowingstrokepromptlyreversespoststrokecellularimmunealterations
AT heuerchristin clinicalimprovementfollowingstrokepromptlyreversespoststrokecellularimmunealterations
AT schulzejuliane clinicalimprovementfollowingstrokepromptlyreversespoststrokecellularimmunealterations
AT gellrichjuliane clinicalimprovementfollowingstrokepromptlyreversespoststrokecellularimmunealterations
AT vonsarnowskibettina clinicalimprovementfollowingstrokepromptlyreversespoststrokecellularimmunealterations
AT langnersonke clinicalimprovementfollowingstrokepromptlyreversespoststrokecellularimmunealterations
AT dresselalexander clinicalimprovementfollowingstrokepromptlyreversespoststrokecellularimmunealterations
AT ruhnaujohanna clinicalimprovementfollowingstrokepromptlyreversespoststrokecellularimmunealterations